TAVR for All? The Surgical Perspective

In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the biop...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Xiling Zhang [verfasserIn] Thomas Puehler [verfasserIn] Derk Frank [verfasserIn] Janarthanan Sathananthan [verfasserIn] Stephanie Sellers [verfasserIn] David Meier [verfasserIn] Marcus Both [verfasserIn] Philipp Blanke [verfasserIn] Hatim Seoudy [verfasserIn] Mohammed Saad [verfasserIn] Oliver J. Müller [verfasserIn] Lars Sondergaard [verfasserIn] Georg Lutter [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk

Übergeordnetes Werk:	In: Journal of Cardiovascular Development and Disease - MDPI AG, 2014, 9(2022), 7, p 223
Übergeordnetes Werk:	volume:9 ; year:2022 ; number:7, p 223

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/jcdd9070223

Katalog-ID:	DOAJ036127671

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ036127671
003	DE-627
005	20240414135952.0
007	cr uuu---uuuuu
008	230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/jcdd9070223 \|2 doi
035			\|a (DE-627)DOAJ036127671
035			\|a (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Xiling Zhang \|e verfasserin \|4 aut
245	1	0	\|a TAVR for All? The Surgical Perspective
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.
650		4	\|a aortic valve stenosis
650		4	\|a transcatheter aortic valve replacement (TAVR)
650		4	\|a transcatheter aortic valve implantation (TAVI)
650		4	\|a surgical aortic valve replacement (SAVR)
650		4	\|a low risk
650		4	\|a intermediate risk
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a Thomas Puehler \|e verfasserin \|4 aut
700	0		\|a Derk Frank \|e verfasserin \|4 aut
700	0		\|a Janarthanan Sathananthan \|e verfasserin \|4 aut
700	0		\|a Stephanie Sellers \|e verfasserin \|4 aut
700	0		\|a David Meier \|e verfasserin \|4 aut
700	0		\|a Marcus Both \|e verfasserin \|4 aut
700	0		\|a Philipp Blanke \|e verfasserin \|4 aut
700	0		\|a Hatim Seoudy \|e verfasserin \|4 aut
700	0		\|a Mohammed Saad \|e verfasserin \|4 aut
700	0		\|a Oliver J. Müller \|e verfasserin \|4 aut
700	0		\|a Lars Sondergaard \|e verfasserin \|4 aut
700	0		\|a Georg Lutter \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Cardiovascular Development and Disease \|d MDPI AG, 2014 \|g 9(2022), 7, p 223 \|w (DE-627)790616017 \|w (DE-600)2777082-5 \|x 23083425 \|7 nnns
773	1	8	\|g volume:9 \|g year:2022 \|g number:7, p 223
856	4	0	\|u https://doi.org/10.3390/jcdd9070223 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2308-3425/9/7/223 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2308-3425 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2022 \|e 7, p 223

Indexfelder

author_variant	x z xz t p tp d f df j s js s s ss d m dm m b mb p b pb h s hs m s ms o j m ojm l s ls g l gl
matchkey_str	article:23083425:2022----::aroalhsriapr
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.3390/jcdd9070223 doi (DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4 DE-627 ger DE-627 rakwb eng RC666-701 Xiling Zhang verfasserin aut TAVR for All? The Surgical Perspective 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR. aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system Thomas Puehler verfasserin aut Derk Frank verfasserin aut Janarthanan Sathananthan verfasserin aut Stephanie Sellers verfasserin aut David Meier verfasserin aut Marcus Both verfasserin aut Philipp Blanke verfasserin aut Hatim Seoudy verfasserin aut Mohammed Saad verfasserin aut Oliver J. Müller verfasserin aut Lars Sondergaard verfasserin aut Georg Lutter verfasserin aut In Journal of Cardiovascular Development and Disease MDPI AG, 2014 9(2022), 7, p 223 (DE-627)790616017 (DE-600)2777082-5 23083425 nnns volume:9 year:2022 number:7, p 223 https://doi.org/10.3390/jcdd9070223 kostenfrei https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 kostenfrei https://www.mdpi.com/2308-3425/9/7/223 kostenfrei https://doaj.org/toc/2308-3425 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 7, p 223
spelling	10.3390/jcdd9070223 doi (DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4 DE-627 ger DE-627 rakwb eng RC666-701 Xiling Zhang verfasserin aut TAVR for All? The Surgical Perspective 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR. aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system Thomas Puehler verfasserin aut Derk Frank verfasserin aut Janarthanan Sathananthan verfasserin aut Stephanie Sellers verfasserin aut David Meier verfasserin aut Marcus Both verfasserin aut Philipp Blanke verfasserin aut Hatim Seoudy verfasserin aut Mohammed Saad verfasserin aut Oliver J. Müller verfasserin aut Lars Sondergaard verfasserin aut Georg Lutter verfasserin aut In Journal of Cardiovascular Development and Disease MDPI AG, 2014 9(2022), 7, p 223 (DE-627)790616017 (DE-600)2777082-5 23083425 nnns volume:9 year:2022 number:7, p 223 https://doi.org/10.3390/jcdd9070223 kostenfrei https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 kostenfrei https://www.mdpi.com/2308-3425/9/7/223 kostenfrei https://doaj.org/toc/2308-3425 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 7, p 223
allfields_unstemmed	10.3390/jcdd9070223 doi (DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4 DE-627 ger DE-627 rakwb eng RC666-701 Xiling Zhang verfasserin aut TAVR for All? The Surgical Perspective 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR. aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system Thomas Puehler verfasserin aut Derk Frank verfasserin aut Janarthanan Sathananthan verfasserin aut Stephanie Sellers verfasserin aut David Meier verfasserin aut Marcus Both verfasserin aut Philipp Blanke verfasserin aut Hatim Seoudy verfasserin aut Mohammed Saad verfasserin aut Oliver J. Müller verfasserin aut Lars Sondergaard verfasserin aut Georg Lutter verfasserin aut In Journal of Cardiovascular Development and Disease MDPI AG, 2014 9(2022), 7, p 223 (DE-627)790616017 (DE-600)2777082-5 23083425 nnns volume:9 year:2022 number:7, p 223 https://doi.org/10.3390/jcdd9070223 kostenfrei https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 kostenfrei https://www.mdpi.com/2308-3425/9/7/223 kostenfrei https://doaj.org/toc/2308-3425 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 7, p 223
allfieldsGer	10.3390/jcdd9070223 doi (DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4 DE-627 ger DE-627 rakwb eng RC666-701 Xiling Zhang verfasserin aut TAVR for All? The Surgical Perspective 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR. aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system Thomas Puehler verfasserin aut Derk Frank verfasserin aut Janarthanan Sathananthan verfasserin aut Stephanie Sellers verfasserin aut David Meier verfasserin aut Marcus Both verfasserin aut Philipp Blanke verfasserin aut Hatim Seoudy verfasserin aut Mohammed Saad verfasserin aut Oliver J. Müller verfasserin aut Lars Sondergaard verfasserin aut Georg Lutter verfasserin aut In Journal of Cardiovascular Development and Disease MDPI AG, 2014 9(2022), 7, p 223 (DE-627)790616017 (DE-600)2777082-5 23083425 nnns volume:9 year:2022 number:7, p 223 https://doi.org/10.3390/jcdd9070223 kostenfrei https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 kostenfrei https://www.mdpi.com/2308-3425/9/7/223 kostenfrei https://doaj.org/toc/2308-3425 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 7, p 223
allfieldsSound	10.3390/jcdd9070223 doi (DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4 DE-627 ger DE-627 rakwb eng RC666-701 Xiling Zhang verfasserin aut TAVR for All? The Surgical Perspective 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR. aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system Thomas Puehler verfasserin aut Derk Frank verfasserin aut Janarthanan Sathananthan verfasserin aut Stephanie Sellers verfasserin aut David Meier verfasserin aut Marcus Both verfasserin aut Philipp Blanke verfasserin aut Hatim Seoudy verfasserin aut Mohammed Saad verfasserin aut Oliver J. Müller verfasserin aut Lars Sondergaard verfasserin aut Georg Lutter verfasserin aut In Journal of Cardiovascular Development and Disease MDPI AG, 2014 9(2022), 7, p 223 (DE-627)790616017 (DE-600)2777082-5 23083425 nnns volume:9 year:2022 number:7, p 223 https://doi.org/10.3390/jcdd9070223 kostenfrei https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 kostenfrei https://www.mdpi.com/2308-3425/9/7/223 kostenfrei https://doaj.org/toc/2308-3425 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 7, p 223
language	English
source	In Journal of Cardiovascular Development and Disease 9(2022), 7, p 223 volume:9 year:2022 number:7, p 223
sourceStr	In Journal of Cardiovascular Development and Disease 9(2022), 7, p 223 volume:9 year:2022 number:7, p 223
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Journal of Cardiovascular Development and Disease
authorswithroles_txt_mv	Xiling Zhang @@aut@@ Thomas Puehler @@aut@@ Derk Frank @@aut@@ Janarthanan Sathananthan @@aut@@ Stephanie Sellers @@aut@@ David Meier @@aut@@ Marcus Both @@aut@@ Philipp Blanke @@aut@@ Hatim Seoudy @@aut@@ Mohammed Saad @@aut@@ Oliver J. Müller @@aut@@ Lars Sondergaard @@aut@@ Georg Lutter @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	790616017
id	DOAJ036127671
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ036127671</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414135952.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcdd9070223</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ036127671</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiling Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">TAVR for All? The Surgical Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aortic valve stenosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transcatheter aortic valve replacement (TAVR)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transcatheter aortic valve implantation (TAVI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">surgical aortic valve replacement (SAVR)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low risk</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">intermediate risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Puehler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Derk Frank</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janarthanan Sathananthan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Sellers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Meier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcus Both</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philipp Blanke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hatim Seoudy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohammed Saad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver J. Müller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Sondergaard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Lutter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Cardiovascular Development and Disease</subfield><subfield code="d">MDPI AG, 2014</subfield><subfield code="g">9(2022), 7, p 223</subfield><subfield code="w">(DE-627)790616017</subfield><subfield code="w">(DE-600)2777082-5</subfield><subfield code="x">23083425</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7, p 223</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcdd9070223</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2308-3425/9/7/223</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2308-3425</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2022</subfield><subfield code="e">7, p 223</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Xiling Zhang
spellingShingle	Xiling Zhang misc RC666-701 misc aortic valve stenosis misc transcatheter aortic valve replacement (TAVR) misc transcatheter aortic valve implantation (TAVI) misc surgical aortic valve replacement (SAVR) misc low risk misc intermediate risk misc Diseases of the circulatory (Cardiovascular) system TAVR for All? The Surgical Perspective
authorStr	Xiling Zhang
ppnlink_with_tag_str_mv	@@773@@(DE-627)790616017
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	23083425
topic_title	RC666-701 TAVR for All? The Surgical Perspective aortic valve stenosis transcatheter aortic valve replacement (TAVR) transcatheter aortic valve implantation (TAVI) surgical aortic valve replacement (SAVR) low risk intermediate risk
topic	misc RC666-701 misc aortic valve stenosis misc transcatheter aortic valve replacement (TAVR) misc transcatheter aortic valve implantation (TAVI) misc surgical aortic valve replacement (SAVR) misc low risk misc intermediate risk misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc aortic valve stenosis misc transcatheter aortic valve replacement (TAVR) misc transcatheter aortic valve implantation (TAVI) misc surgical aortic valve replacement (SAVR) misc low risk misc intermediate risk misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc aortic valve stenosis misc transcatheter aortic valve replacement (TAVR) misc transcatheter aortic valve implantation (TAVI) misc surgical aortic valve replacement (SAVR) misc low risk misc intermediate risk misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Cardiovascular Development and Disease
hierarchy_parent_id	790616017
hierarchy_top_title	Journal of Cardiovascular Development and Disease
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)790616017 (DE-600)2777082-5
title	TAVR for All? The Surgical Perspective
ctrlnum	(DE-627)DOAJ036127671 (DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4
title_full	TAVR for All? The Surgical Perspective
author_sort	Xiling Zhang
journal	Journal of Cardiovascular Development and Disease
journalStr	Journal of Cardiovascular Development and Disease
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Xiling Zhang Thomas Puehler Derk Frank Janarthanan Sathananthan Stephanie Sellers David Meier Marcus Both Philipp Blanke Hatim Seoudy Mohammed Saad Oliver J. Müller Lars Sondergaard Georg Lutter
container_volume	9
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Xiling Zhang
doi_str_mv	10.3390/jcdd9070223
author2-role	verfasserin
title_sort	tavr for all? the surgical perspective
callnumber	RC666-701
title_auth	TAVR for All? The Surgical Perspective
abstract	In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.
abstractGer	In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.
abstract_unstemmed	In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	7, p 223
title_short	TAVR for All? The Surgical Perspective
url	https://doi.org/10.3390/jcdd9070223 https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4 https://www.mdpi.com/2308-3425/9/7/223 https://doaj.org/toc/2308-3425
remote_bool	true
author2	Thomas Puehler Derk Frank Janarthanan Sathananthan Stephanie Sellers David Meier Marcus Both Philipp Blanke Hatim Seoudy Mohammed Saad Oliver J. Müller Lars Sondergaard Georg Lutter
author2Str	Thomas Puehler Derk Frank Janarthanan Sathananthan Stephanie Sellers David Meier Marcus Both Philipp Blanke Hatim Seoudy Mohammed Saad Oliver J. Müller Lars Sondergaard Georg Lutter
ppnlink	790616017
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/jcdd9070223
callnumber-a	RC666-701
up_date	2024-07-03T18:50:53.362Z
_version_	1803584959533809664
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ036127671</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414135952.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcdd9070223</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ036127671</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9d49de55c1b24019aa3eb2b64f5aafa4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiling Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">TAVR for All? The Surgical Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aortic valve stenosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transcatheter aortic valve replacement (TAVR)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transcatheter aortic valve implantation (TAVI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">surgical aortic valve replacement (SAVR)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low risk</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">intermediate risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Puehler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Derk Frank</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janarthanan Sathananthan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Sellers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Meier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcus Both</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philipp Blanke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hatim Seoudy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohammed Saad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver J. Müller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Sondergaard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Lutter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Cardiovascular Development and Disease</subfield><subfield code="d">MDPI AG, 2014</subfield><subfield code="g">9(2022), 7, p 223</subfield><subfield code="w">(DE-627)790616017</subfield><subfield code="w">(DE-600)2777082-5</subfield><subfield code="x">23083425</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7, p 223</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcdd9070223</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9d49de55c1b24019aa3eb2b64f5aafa4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2308-3425/9/7/223</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2308-3425</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2022</subfield><subfield code="e">7, p 223</subfield></datafield></record></collection>
score	7.400692

Nicht das Richtige dabei?

Schreiben Sie uns!

TAVR for All? The Surgical Perspective

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?